Teplizumab

Most diabetes care and education specialists said they believe it is important to screen for presymptomatic type 1 diabetes, though some said they had limited knowledge regarding teplizumab-mzwv, according to a presenter.

NEW ORLEANS — In part three of a three-part video exclusive series, Jonathan D. Leffert, MD, talks with Kimber Simmons, MD, MS, about how providers should discuss treatments for people with early-stage type 1 diabetes.

NEW ORLEANS — In part one of a three-part video exclusive series, Jonathan D. Leffert, MD, talks with Anna Casu, MD, about the preclinical stages of type 1 diabetes and who should be screened for the disease.

Hybrid closed-loop insulin delivery systems are more cost-effective for treating type 1 diabetes than immune therapies unless the effects of immune therapies are persistent over a lifetime after one course, according to a speaker.

New guidance on obesity management and cardiovascular disease screening for people with diabetes are among the updates in the American Diabetes Association’s 2024 Standards of Care.

Susan Weiner, MS, RDN, CDN, CDCES, FADCES, talks with Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP, about nuances of using SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes, and a therapy for delaying type 1 diabetes onset.

Children with new-onset type 1 diabetes had better preservation of beta-cell function with two 12-day courses of teplizumab compared with those receiving placebo, according to findings published in The New England Journal of Medicine.

The Healio and Endocrine Today Editors have compiled a list of the top endocrinology news stories from 2022.

Last week, the FDA announced that it has approved Tzield to delay the onset of type 1 diabetes in adults and children aged 8 years and older with stage 2 type 1 diabetes.

The FDA has approved teplizumab to delay the onset of type 1 diabetes for both adults and children aged 8 years and older with stage 2 type 1 diabetes, according to an agency press release.